NEW YORK – (BUSINESS WIRE) – October 25, 2021–
WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of buyers of securities of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) between January 13, 2020 and September 3 2021 inclusive (the “Class Period”). A class action has already been filed. If you want to serve as the principal applicant, you must move the court no later than December 21, 2021.
SO WHAT: If you purchased BioMarin securities during the Class Period, you may be entitled to compensation without payment of any costs or reimbursable charges through a contingency fee agreement.
WHAT TO DO NEXT: To join the BioMarin class action lawsuit, go to http://www.rosenlegal.com/cases-register-2185.html or call Phillip Kim, Esq. toll free at 866-767-3653 or by emailing [email protected] or [email protected] for information on the class action. A class action has already been filed. If you want to serve as the principal applicant, you must move the court no later than December 21, 2021. A principal plaintiff is a representative party acting on behalf of the other members of the class to direct the litigation.
WHY THE ROSEN LAW: We encourage investors to select qualified advisors with a track record of success in leadership roles. Often, companies providing reviews do not have comparable experience, resources or peer recognition. Be wise in choosing the right lawyer. Rosen law firm represents investors around the world, focusing its practice on class actions in securities and derivative litigation between shareholders. Rosen law firm has secured the largest securities class action settlement against a Chinese company. Rosen law firm was ranked # 1 by ISS Securities Class Action Services for the number of securities class action settlements in 2017. The firm has been ranked in the top 4 every year since 2013 and has recovered hundreds millions of dollars for investors. In 2019 alone, the company raised more than $ 438 million for investors. In 2020, founding partner Laurence Rosen was appointed by law360 as the Titan of Plaintiffs’ Bar. Many of the firm’s lawyers have been recognized by Lawdragon and Super Lawyers.
CASE DETAILS: According to the lawsuit, defendants throughout the litigation period made false and / or misleading statements and / or failed to disclose that: (1) BMN 307, an AAV5-mediated gene therapy, was less safe than BioMarin had led investors to believe; (2) the safety profile of BMN 307 made it likely that the United States Food and Drug Administration (FDA) would put a clinical stop to the Phase 1/2 study of Phearless; (3) as a result, the Company overestimated the clinical and commercial prospects of BMN 307; and (4) accordingly, the Company’s public statements were materially false and misleading at all material times. When the real details entered the market, the lawsuit claims that investors have suffered damage.
No class has been certified. Until a group is certified, you are not represented by a lawyer unless you hire one. You can choose the lawyer of your choice. You can also remain an absent group member and do nothing at this point. The ability of an investor to participate in any potential future recovery does not depend on whether he or she is a lead applicant.
Lawyer advertising. Previous results do not guarantee a similar result.
CONTACT: Laurence Rosen, Esq.
275 Madison Avenue, 40th Floor
Toll free: (866) 767-3653
KEYWORD: UNITED STATES NORTH AMERICA NEW YORK
INDUSTRY KEYWORD: PROFESSIONAL LEGAL SERVICES
Copyright Business Wire 2021.
PUB: 25/10/2021 18: 09 / DISC: 25/10/2021 18:09
Copyright Business Wire 2021.